Victoria Collings

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

J. Bartoli-Abdou, Alexander Thomas Cohen, Lucy Vernon, Victoria Collings et autres

Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT). Aim To compare thrombotic …

gb (code pays fourni par la source)

Comparable Outcomes Using Low-Dose Apixaban and Anti-Xa Monitoring and Vitamin-K Antagonists in Patients with Renal Replacement Therapy

John Bartoli-Abdou, Ander Cohen, Lucy Vernon, Victoria Collings et autres

Background: Guidelines recommend the use of oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the USA, apixaban is contraindicated for use in patients with end stage renal disease (ESRD) receiving renal replacement therapy (RRT). Aim: …

gb (code pays fourni par la source)

An evaluation of the impact of the Lambeth PCN pharmacist anticoagulation skills development project

H Shuker, Reem Kayyali, Srikala Bhandary, Victoria Collings

Abstract Background Atrial Fibrillation (AF) is a prevalent heart condition linked to significant morbidity and mortality due to its association with stroke.1 Despite the clear benefits of anticoagulation in reducing stroke risk, its underuse and suboptimal monitoring remain a concern.2 Aim This …

us, gb, au (code pays fourni par la source)

Clinical outcomes of patients receiving long-term fondaparinux for thrombotic antiphospholipid syndrome

Buse Bor, Andrew J. Doyle, J. Bartoli-Abdou, Anthony Hackett et autres

Introduction Vitamin-K antagonists (VKA) are considered the first-line anticoagulants for thrombotic antiphospholipid syndrome (TAPS), particularly with triple positivity or arterial events. However, thrombotic recurrence remains high despite anticoagulation and other clinical issues may arise. Long-term parenteral anticoagulants may therefore be considered, however …

gb, dk (code pays fourni par la source)

Factor Xa Inhibitor Plasma Concentrations and Clinical Outcomes in Patients Weighing ≤50 kg—Experience from Four UK Centers

Victoria Speed, Rachel E. Clapham, J. Bartoli-Abdou, Katherine Stirling et autres

Background In recent years, factor Xa inhibitor (FXaI) research at the extremes of bodyweight has focused on obesity (>120 kg), but significant gaps in clinical outcome data and pharmacokinetic studies exist in those weighing ≤50 kg.[ 1 ] [ 2 ] In …

gb (code pays fourni par la source)

PB0506 Clinical Outcomes of Patients Prescribed Apixaban in End Stage Renal Disease Undergoing Dialysis. Results from a Tertiary Centre in UK - A Retrospective Observational Audit

J. Bartoli-Abdou, Urapee Chaichana, N. Moore, Lai Wei et autres

cohort, with notably 3 major gastrointestinal bleeds.

gb (code pays fourni par la source)

PB0496 Bleeding Risk with Long-Term Fondaparinux Use for Secondary Prevention of Thromboembolism at a Tertiary Centre in the UK: A Retrospective Observational Audit

J. Bartoli-Abdou, A. E. Doyle, Karen A. Breen, Victoria Collings et autres

PB0458 Pharmacokinetic Analysis of Apixaban in Patients with End Stage Renal Disease Undergoing Dialysis, Real World Data from a Tertiary Centre in London, UK – A Retrospective Audit

J. Bartoli-Abdou, U. Chaichana, Nathan A. Moore, Lai Wei et autres

Figure: Incidence of major bleeding and recurrent VTE between 3 and 9 months after PE.Conclusion(s): Between 2014 and 2019 the use of prolonged anticoagulation after a first PE increased.Meanwhile, the incidence of major bleeding remained stable, whereas the incidence of recurrent VTE …

gb (code pays fourni par la source)

PB0436 Long-Term Use of Fondaparinux in Patients with Thrombotic Antiphospholipid Syndrome - A Retrospective Audit of Clinical Outcomes

Buse Bor, Ali Doyle, J. Bartoli-Abdou, A. Hackett et autres

dk, gb (code pays fourni par la source)

Direct oral anticoagulant plasma concentrations in obese and high body weight patients: An observational study

Anne‐Céline Martin, William T. B. Thomas, Zahra Mahir, Maeve P. Crowley et autres

fr, gb, ca, ie (code pays fourni par la source)

Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study

Anne‐Céline Martin, William T. B. Thomas, Zahra Mahir, Maeve P. Crowley et autres

BACKGROUND: Direct oral anticoagulants (DOACs) are prescribed for atrial fibrillation (AF) and venous thromboembolism (VTE) and both occur more frequently in obese patients. Outcomes from DOAC trials included few individuals ≥ 120 kg leading to uncertainty whether high body weight (BW) reduces …

fr, gb, ie (code pays fourni par la source)

4CPS-030 Evaluation of pharmacist-led cardiovascular services within primary care, provided by cardiovascular pharmacists

K. T. Koch, C Meddings, Victoria Collings, Natalie Bidad

Background There is a limited amount of evidence demonstrating the benefit of pharmacy-led community services managing cardiovascular diseases. With an ever increasing demand on hospitals and a focus on preventing admission, the cardiovascular pharmacy team at a hospital is delivering both virtual …

gb (code pays fourni par la source)